Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2016

21.06.2016 | Brief Report

Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung

verfasst von: Brennan McCullar, Manjari Pandey, George Yaghmour, Felicia Hare, Kruti Patel, Matthew Stein, Rebecca Feldman, Jason C. Chandler, Michael G. Martin

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Small cell carcinoma of the breast is a rare, aggressive form of breast cancer that is associated with extremely poor outcomes [1]. In an effort to identify possible targets for treatment, we utilized comprehensive genomic profiling in small cell carcinoma of the breast. Under an IRB approved protocol, we identified patients with small cell carcinoma of the breast and small cell carcinoma of the lung profiled by Caris Life Sciences between 2007 and 2015. Tumors were assessed with up to 25 immunohistochemical stains, in situ hybridization of cMET, EGFR, HER2, PIK3CA, and TOP2A, and next generation sequencing as well as Sanger sequencing of 47 genes. 19 patients with small cell carcinoma of the breast were identified, median age was 58 years (range 37–79) and 42 % had metastatic disease at presentation; for comparison, 58 patients with small cell carcinoma of the lung were identified (66 [36–86], 65 % metastatic). By immunohistochemistry, 31 % of small cell carcinoma of the breast patients expressed ER, 13 % expressed PR, and 16 % expressed AR; small cell carcinoma of the lung patients expressed ER 0 %, PR 2 %, and AR 6 %. Small cell carcinoma of the breast and small cell carcinoma of the lung patients had similar patterns of other immunohistochemical expression (0 v 0 % PDL1, 50 v 42 % PD1, and 77 v 95 % TOP2A, respectively). All small carcinoma of the breast and small cell carcinoma of the lung patients were negative for HER2 and cMET amplification by in situ hybridization. Next generation sequencing revealed TP53 mutations in 75 % of patients both with small cell carcinoma of the breast and small cell carcinoma of the lung and PIK3CA mutations in 33 % of small cell carcinoma of the breast patients but no small cell carcinoma of the lung patients (Fisher’s exact test p = 0.005, OR 0.02 [0.00–0.52]). No other mutations were found in small cell carcinoma of the breast patients and no other mutation occurred in over 10 % of small cell carcinoma of the lung patients except RB1 in 19 % (p = 0.31). Small cell carcinoma of the breast is an aggressive tumor with few therapeutic options. Molecular profiling suggests many similarities between small cell carcinoma of the breast and small cell carcinoma of the lung with the exception an increased incidence of PIK3CA mutations in small cell carcinoma of the breast, which may have therapeutic implications.
Literatur
2.
Zurück zum Zitat Grossman RA, Pedroso FE, Byrne MM, Koniaris LG, Misra S (2011) Does surgery or radiation therapy impact survival for patients with extrapulmonary small cell cancers? J Surg Oncol 104(6):604–612. doi:10.1002/jso.21976 CrossRefPubMed Grossman RA, Pedroso FE, Byrne MM, Koniaris LG, Misra S (2011) Does surgery or radiation therapy impact survival for patients with extrapulmonary small cell cancers? J Surg Oncol 104(6):604–612. doi:10.​1002/​jso.​21976 CrossRefPubMed
4.
Zurück zum Zitat Lopez-Bonet E, Alonso-Ruano M, Barraza G, Vazquez-Martin A, Bernado L, Menendez JA (2008) Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep 20(6):1369–1374PubMed Lopez-Bonet E, Alonso-Ruano M, Barraza G, Vazquez-Martin A, Bernado L, Menendez JA (2008) Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep 20(6):1369–1374PubMed
7.
Zurück zum Zitat Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B et al (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. New Engl J Med 327(23):1618–1624CrossRef Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, Brodin O, Joss RA, Kies MS, Lebeau B et al (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. New Engl J Med 327(23):1618–1624CrossRef
10.
Zurück zum Zitat Hahn AW, Giri S, Patel D, Sluder H, Vanderwalde A, Martin MG (2015) Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis. J Natl Compr Canc Netw 13(10):1181–1185CrossRef Hahn AW, Giri S, Patel D, Sluder H, Vanderwalde A, Martin MG (2015) Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis. J Natl Compr Canc Netw 13(10):1181–1185CrossRef
14.
Zurück zum Zitat Kitakata H, Yasumoto K, Sudo Y, Minato H, Takahashi Y (2007) A case of primary small cell carcinoma of the breast. Breast Cancer 14(4):414–419CrossRef Kitakata H, Yasumoto K, Sudo Y, Minato H, Takahashi Y (2007) A case of primary small cell carcinoma of the breast. Breast Cancer 14(4):414–419CrossRef
15.
Zurück zum Zitat Shin SJ, DeLellis RA, Ying L, Rosen PP (2000) Small cell carcinoma of the breast: a clinicopathologic and immunohistochemical study of nine patients. Am J Surg Pathol 24(9):1231–1238CrossRef Shin SJ, DeLellis RA, Ying L, Rosen PP (2000) Small cell carcinoma of the breast: a clinicopathologic and immunohistochemical study of nine patients. Am J Surg Pathol 24(9):1231–1238CrossRef
16.
Zurück zum Zitat Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti–pd-1 antibody in cancer. N Engl J Med 366(26):2443–2454. doi:10.1056/NEJMoa1200690 CrossRefPubMedPubMedCentral Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti–pd-1 antibody in cancer. N Engl J Med 366(26):2443–2454. doi:10.​1056/​NEJMoa1200690 CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Antonia JS, Bendell JC, Taylor MH, Calvo E, Jaeger D, De Braud FG, Ott PA, Pietanza MC, Horn L, Le DT, Morse M, Lopez-Martin JA, Ascierto PA, Christensen O, Grosso J, Simon JS, Lin C, Eder JP (2015) Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC). J Clin Oncol 33 suppl; abstr 7503 Antonia JS, Bendell JC, Taylor MH, Calvo E, Jaeger D, De Braud FG, Ott PA, Pietanza MC, Horn L, Le DT, Morse M, Lopez-Martin JA, Ascierto PA, Christensen O, Grosso J, Simon JS, Lin C, Eder JP (2015) Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC). J Clin Oncol 33 suppl; abstr 7503
18.
Zurück zum Zitat Ott PA, Fernandez ME, Hiret S, Kim D, Moss RA, Winser T, Yuan S, Cheng JD, Piperdi B, Mehnert JM (2015) Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results. J Clin Oncol 33, suppl; abstr 7502 Ott PA, Fernandez ME, Hiret S, Kim D, Moss RA, Winser T, Yuan S, Cheng JD, Piperdi B, Mehnert JM (2015) Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results. J Clin Oncol 33, suppl; abstr 7502
19.
Zurück zum Zitat Hua W, Sa KD, Zhang X, Jia LT, Zhao J, Yang AG, Zhang R, Fan J, Bian K (2015) MicroRNA-139 suppresses proliferation in luminal type breast cancer cells by targeting Topoisomerase II alpha. Biochem Biophys Res Commun 463(4):1077–1083. doi:10.1016/j.bbrc.2015.06.061 CrossRefPubMed Hua W, Sa KD, Zhang X, Jia LT, Zhao J, Yang AG, Zhang R, Fan J, Bian K (2015) MicroRNA-139 suppresses proliferation in luminal type breast cancer cells by targeting Topoisomerase II alpha. Biochem Biophys Res Commun 463(4):1077–1083. doi:10.​1016/​j.​bbrc.​2015.​06.​061 CrossRefPubMed
20.
Zurück zum Zitat Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P (2008) HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100(1):14–20. doi:10.1093/jnci/djm252 CrossRefPubMed Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P (2008) HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100(1):14–20. doi:10.​1093/​jnci/​djm252 CrossRefPubMed
21.
Zurück zum Zitat Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LFA, de Jong D, Van de Vijver MJ, Van’t Veer LJ, Peterse JL (2008) Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216(2):141–150. doi:10.1002/path.2407 CrossRefPubMed Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LFA, de Jong D, Van de Vijver MJ, Van’t Veer LJ, Peterse JL (2008) Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216(2):141–150. doi:10.​1002/​path.​2407 CrossRefPubMed
23.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Goodwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. doi:10.1016/S0140-6736(11)60993-8 CrossRef Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Goodwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378(9793):771–784. doi:10.​1016/​S0140-6736(11)60993-8 CrossRef
24.
Zurück zum Zitat BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS (2009) Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361(8):766–776. doi:10.1056/NEJMoa0810818 CrossRef BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS (2009) Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361(8):766–776. doi:10.​1056/​NEJMoa0810818 CrossRef
25.
Zurück zum Zitat Kanat O, Kilickap S, Korkmaz T, Oven B, Canhoroz M, Cubukcu E, Tolunay S, Evrensel T, Manavoglu O (2011) Primary small cell carcinoma of the breast: report of seven cases and review of the literature. Tumori 97(4):473–478. doi:10.1700/950.10400 CrossRefPubMed Kanat O, Kilickap S, Korkmaz T, Oven B, Canhoroz M, Cubukcu E, Tolunay S, Evrensel T, Manavoglu O (2011) Primary small cell carcinoma of the breast: report of seven cases and review of the literature. Tumori 97(4):473–478. doi:10.​1700/​950.​10400 CrossRefPubMed
26.
Zurück zum Zitat Alkaied H, Harris K, Brenner A, Awasum M, Varma S (2012) Does Hormonal Therapy Have a Therapeutic Role in Metastatic Primary Small Cell Neuroendocrine Breast Carcinoma? Case Report and Literature Review. Clin Breast Cancer 12(3):226–230. doi:10.1016/j.clbc.2012.01.008 CrossRefPubMed Alkaied H, Harris K, Brenner A, Awasum M, Varma S (2012) Does Hormonal Therapy Have a Therapeutic Role in Metastatic Primary Small Cell Neuroendocrine Breast Carcinoma? Case Report and Literature Review. Clin Breast Cancer 12(3):226–230. doi:10.​1016/​j.​clbc.​2012.​01.​008 CrossRefPubMed
28.
Zurück zum Zitat Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092):424–430CrossRef Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092):424–430CrossRef
29.
Zurück zum Zitat Jerusalem G, Rorive A, Collignon J (2014) Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. Breast Cancer 6:43–57. doi:10.2147/BCTT.S38679 CrossRefPubMed Jerusalem G, Rorive A, Collignon J (2014) Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. Breast Cancer 6:43–57. doi:10.​2147/​BCTT.​S38679 CrossRefPubMed
31.
Zurück zum Zitat Encinas G, Maistro S, Pasini FS, Katayama ML, Brentani MM, Bock GH, Folgueira MA (2015) Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis. Rev Assoc Med Bras 61(5):474–483. doi:10.1590/1806-9282.61.05.474 CrossRefPubMed Encinas G, Maistro S, Pasini FS, Katayama ML, Brentani MM, Bock GH, Folgueira MA (2015) Somatic mutations in breast and serous ovarian cancer young patients: a systematic review and meta-analysis. Rev Assoc Med Bras 61(5):474–483. doi:10.​1590/​1806-9282.​61.​05.​474 CrossRefPubMed
Metadaten
Titel
Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung
verfasst von
Brennan McCullar
Manjari Pandey
George Yaghmour
Felicia Hare
Kruti Patel
Matthew Stein
Rebecca Feldman
Jason C. Chandler
Michael G. Martin
Publikationsdatum
21.06.2016
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2016
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3867-z

Weitere Artikel der Ausgabe 1/2016

Breast Cancer Research and Treatment 1/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.